Literature DB >> 7867672

Are we doing too many animal biodisposition investigations before phase I studies in man? A re-evaluation of the timing and extent of ADME studies.

D B Campbell1.   

Abstract

This commentary attempts to re-evaluate, from a scientific standpoint, the timing and usefulness of undertaking detailed kinetic and metabolic studies in many animals from several species, and extrapolating the findings to man. This reappraisal is now possible due to the conditional acceptance of harmonised guidelines on toxicokinetics at ICH2 in Orlando in 1993, the results from which can provide much of the information that is required to design and validate safety studies and to extrapolate exposure or safety margins to man.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7867672     DOI: 10.1007/BF03188932

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  10 in total

1.  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Authors:  C C Peck; W H Barr; L Z Benet; J Collins; R E Desjardins; D E Furst; J G Harter; G Levy; T Ludden; J H Rodman
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

Review 2.  The molecular biology of cytochrome P450s.

Authors:  F J Gonzalez
Journal:  Pharmacol Rev       Date:  1988-12       Impact factor: 25.468

3.  New strategies in drug development and clinical evaluation: the population approach. Commentary on an action for co-operative research.

Authors:  L P Balant; M Rowland; L Aarons; F Mentré; P L Morselli; J L Steimer; S Vozeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

Authors:  J B Houston
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

Review 5.  Elimination of drugs by passive diffusion from blood to intestinal lumen: factors influencing nonbiliary excretion by the intestinal tract.

Authors:  P G Dayton; Z H Israili; J D Henderson
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

Review 6.  The melanin binding of drugs and its implications.

Authors:  R M Ings
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

7.  Induction of cytochrome P450IIE1 in the obese overfed rat.

Authors:  J L Raucy; J M Lasker; J C Kraner; D E Salazar; C S Lieber; G B Corcoran
Journal:  Mol Pharmacol       Date:  1991-03       Impact factor: 4.436

8.  Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment.

Authors:  P N Zannikos; A M Bandyopadhyay; L W Robertson; R A Blouin
Journal:  Int J Obes Relat Metab Disord       Date:  1994-06

9.  Predicting the hepatic clearance of xenobiotics in humans from in vitro data.

Authors:  B A Hoener
Journal:  Biopharm Drug Dispos       Date:  1994-05       Impact factor: 1.627

10.  Influence of input rates on (+/-)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers.

Authors:  V Carrara; H Porchet; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  10 in total
  1 in total

1.  Quantification of small molecule drugs in biological tissue sections by imaging mass spectrometry using surrogate tissue-based calibration standards.

Authors:  Nozomi Takai; Yukari Tanaka; Hideo Saji
Journal:  Mass Spectrom (Tokyo)       Date:  2014-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.